Takeda Pharmaceutical Company Ltd
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
- Conditions
- Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell LymphomaSolid TumorsInflammatory Myofibroblastic Tumors
- Interventions
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Takeda
- Registration Number
- NCT04260009
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
- Conditions
- Peripheral T Cell LymphomaPediatric Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2019-12-30
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 95
- Registration Number
- NCT04213209
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 77
- Registration Number
- NCT04206605
- Locations
- 🇺🇸
University of South Florida Asthma, Allergy & Immunology, Tampa, Florida, United States
🇩🇪Universitaetsklinikum Leipzig AoeR, Leipzig, Sachsen, Germany
🇺🇸Medical Research of Arizona, Scottsdale, Arizona, United States
A Study With [18F]MNI-1054 to Determine Lysine -Specific Demethylase 1A (LSD1) Brain Enzyme Occupancy of TAK-418 After Single-Dose Oral Administration in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [18F]MNI-1054 (radiotracer)
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Takeda
- Target Recruit Count
- 7
- Registration Number
- NCT04202497
- Locations
- 🇺🇸
Invicro, A Konica Minolta Company, New Haven, Connecticut, United States
A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection
- Conditions
- Helicobacter Pylori
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 510
- Registration Number
- NCT04198363
- Locations
- 🇨🇳
The First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
A Study of TAK-079 in People With Generalized Myasthenia Gravis
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 36
- Registration Number
- NCT04159805
- Locations
- 🇺🇸
Neurology and Sleep Disorders Clinic, Columbia, Missouri, United States
🇮🇹Fondazione Policlinico Universitario A Gemelli, Roma, Lazio, Italy
🇺🇸The University of Arizona Medical Center, Tucson, Arizona, United States
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 45
- Registration Number
- NCT04157517
- Locations
- 🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Norris Cotton Cancer Center Lebanon, Lebanon, New Hampshire, United States
🇺🇸Morristown Medical Center, Morristown, New Jersey, United States
A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-123 After Intravenous Infusion in Japanese Healthy Adult Male Participants
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 10
- Registration Number
- NCT04155567
- Locations
- 🇯🇵
Sekino Clinical Pharmacology Clinic, Toshima-ku, Tokyo, Japan
A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal)
- Conditions
- Relapse and/or Refractory Multiple Myeloma
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 62
- Registration Number
- NCT04135963
- Locations
- 🇵🇹
Instituto Portugues de Oncologia de Lisboa Francisco Gentil (IPO), Lisboa, Portugal
🇵🇹Centro Hospitalar Lisboa Norte EPE - Hospital de Santa Maria, Lisboa, Portugal
🇵🇹Centro Hospitalar Universitario de Sao Joao, EPE,, Porto, Portugal
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 354
- Registration Number
- NCT04129502
- Locations
- 🇮🇹
AORN Dei Colli- Ospedale Monaldi Napoli, Napoli, Campania, Italy
🇺🇦Private Enterprise Private Manufacturing Company Acinus, Kropyvnytskyi, Ukraine
🇨🇳Icahn School of Medicine at Mount Sinai, Beijing, China